Imaging with a new PET agent for SSTR2 positive diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research investigates the safety and effectiveness of a new dual receptor targeting PET radiotracer, 68Ga-FAPI-LM3, in patients with SSTR2 positive diseases. Participants will undergo both 68Ga-FAPI-LM3 and 18F-FDG PET/CT scans to assess the diagnostic accuracy of the new imaging agent compared to the standard. The study will evaluate biodistribution, radiation dosimetry, and the number of detected lesions. The goal is to determine if 68Ga-FAPI-LM3 provides better imaging results for these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (i) adult patients (aged 18 years or order);
* (ii) patients with suspected or newly diagnosed or previously malignant disease, with either FAP or SSTR2 positive expression (supporting evidence may include MRI, CT, and pathology report etc);
* (iii) patients who had scheduled both 18F-FDG and 68Ga-FAPI-LM3 PET/CT scans;
* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* (i) patients with non-malignant disease;
* (ii) patients with pregnancy;
* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Where it's running

• The First Affiliated Hospital of Xiamen University
  Xiamen, Fujian, China Recruiting

Study contacts

• Study coordinator: Long Sun, PhD
• Email: 13178352662@163.com
• Phone: 86 0592-2137077

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients

  This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690970

• Imaging with 68Ga-PSFA in patients with specific cancer markers

  This study is testing a new imaging agent to see if it can help find cancer spots in patients with certain cancer markers.

  Recruiting Early Phase 1 First Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT06387381

• PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults

  This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07618936

• 68Ga-FL-031 PET for diagnosing and staging cancer

  This project will test whether 68Ga-FL-031 PET imaging, compared with 18F-FDG PET, can detect and stage small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other tumors in adults.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07301801

• Classifying duodenal polyps in familial adenomatous polyposis

  This project will test two risk models to see if they better predict dangerous duodenal polyps and cancer risk in people with genetically confirmed FAP.

  Recruiting at 2 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan, MI and 1 other locations · NCT07199127

• FAPI-PET/CT imaging for diagnosing and staging pancreatic cancer

  This study will try 18F‑FAPI‑74 PET/CT scans in adults with suspected or recurrent pancreatic cancer to see if they detect lymph node spread and distant metastases more accurately.

  Recruiting Phase 2/3 Turku University Hospital · Turku · NCT07098598

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.